سعر اريسا 250مجم 30 قرص 2026

Iressa (gefitinib) 250 mg tablets, pack of 30 (AstraZeneca).

• First-line treatment of metastatic non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations; not established for other EGFR mutations.Population: Adults with metastatic EGFR-mutated NSCLCDailyMed (U.S. National Library of Medicine)

• Most frequent (>20% and greater than placebo): skin reactions (47%) and diarrhoea (29%).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• None listed in the US label.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Interstitial lung disease (1.3%, some fatal): withhold and investigate worsening dyspnoea, cough or fever; discontinue if ILD confirmed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatotoxicity (ALT increase 11.4%; fatal 0.04%): obtain periodic liver function tests.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Gastrointestinal perforation (0.1%): discontinue permanently.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inducers (e.g. rifampicin, phenytoin)Decrease gefitinib concentrations; increase dose to 500 mg daily.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole)Increase gefitinib concentrations; monitor for adverse reactions.DailyMed (U.S. National Library of Medicine)
• Drugs raising gastric pH (PPIs, H2 antagonists, antacids)May reduce gefitinib levels; avoid PPIs if possible, otherwise take gefitinib 12 h after/before the PPI; separate from H2 antagonists or antacids by 6 h.DailyMed (U.S. National Library of Medicine)

• Based on mechanism and animal data (fetotoxicity and neonatal death below the human dose), can cause fetal harm; advise pregnant women of the risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Unknown whether excreted in human milk (rat milk levels 11-19-fold higher than blood); advise discontinuing breastfeeding during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Gefitinib: Inhibits EGFR tyrosine kinase signalling in tumour cells carrying activating EGFR mutations (exon 19 deletion, exon 21 L858R).